Case Study Shows Asbestos in Talc Causes Mesothelioma

This study was the first large case series to identify contaminated cosmetic talc as the cause of mesothelioma and the first to use background controls dictated by no known asbestos exposure. It emphasizes the continued risk from common cosmetic products once thought to be safe for all. “I would tell people that there is no regulation for talc, and that if there is a safer alternative, than I would advise them to do that,” Moline said. “I would not recommend people use talcum powder.” The post Case Study Shows Asbestos in Talc Causes Mesothelioma appeared first on Mesothelioma Center - Vital Services for Cancer Patients &Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

The Science Advisory Committee on Chemicals found considerable failings and an underestimation of danger to the general public in a draft risk evaluation of asbestos submitted earlier this year by the U.S. Environmental Protection Agency. SACC, which serves as a scientific, peer-review mechanism for the EPA, released its recommendations last week in the ongoing governmental reevaluation of asbestos. This is the latest step in the amended Toxic Substances Control Act that requires the EPA to conduct evaluations on specific chemicals to determine whether they present unreasonable risk under conditions of use. The committee w...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Recombinant Immunotoxins (RITs) are chimeric molecules composed of an antigen binding domain and toxin. The antigen binding domain component targets the cancer cell and delivers the toxin component to the cell. However, the efficacy of RITs is limited by their short half-life once they are in the patient. To address this problem, investigators at the National Cancer Institute (NCI) increased the half-life of RITs using polyethylene glycol (PEG).In specific embodiments, the antigen-binding fragment targets mesothelin, and the toxin is a fragment of Pseudomonas exotoxin (PE). Mesothelin is highly expressed in many human canc...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
ConclusionThe decision to utilize CRS-HIPEC should involve a multidisciplinary team approach and evaluation of prognostic factors to balance the short-term morbidity of the operation with maximum long-term benefits. Large, multi-institutional groups and ongoing trials hold promise for clarifying the role of CRS-HIPEC in peritoneal surface malignancies.
Source: Journal of Gastrointestinal Surgery - Category: Surgery Source Type: research
Abstract RNA interference (RNAi), a potent post-transcriptional gene-silencing action, has received considerable attentions as a novel therapeutic tool to treat intractable cancers. In recent days, we have developed a novel RNAi-based therapeutic formulation, DFP-10825, for the treatment of intractable advanced cancers developed in coelomic cavities. DFP-10825 was composed of chemically synthesized short hairpin RNA (shRNA) against thymidylate synthase (TS), a key enzyme for cancer proliferation, and cationic liposomes, and achieved high therapeutic effect on the mouse models of peritoneally disseminated gastric a...
Source: Advanced Drug Delivery Reviews - Category: Drugs & Pharmacology Authors: Tags: Adv Drug Deliv Rev Source Type: research
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated. The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers. While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I. Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsRadiolabeled anti-mesothelin antibodies could be crucial as a treatment tool and for predicting the eligibility and the response of the patient to radioimmunotherapy through the study of the expression grade of mesothelin. They can be a relevant tool for pancreatic adenocarcinoma, lung cancer, human epidermoid carcinoma, ovarian cancer, malignant mesothelioma in which mesothelin is widely expressed.
Source: Clinical and Translational Imaging - Category: Radiology Source Type: research
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T Abstract Objective: The purpose of the present review was to provide evidence-based guidance about the provision of cytoreductive surgery (crs) with hyperthermic intraperitoneal chemotherapy (hipec) in the treatment of peritoneal cancers. Methods: The guideline was developed by the Program in Evidence-Based Care together with the Surgical Oncology Program at Ontario Health (Cancer Care Ontario) through a systematic review of relevant literature, patient- and caregiver-specific consultation, and internal and external reviews. Results: Re...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
National advocacy group Black Women for Wellness joined more than 170 other nonprofits from 51 countries last week in demanding that Johnson &Johnson stop the worldwide distribution of its iconic Johnson’s Baby Powder. The demand for a global distribution ban stems from the potential for asbestos in talc, which has led to various cancers and thousands of personal injury lawsuits. A majority of talc cases pertain to women and ovarian cancer. A small percentage of the legal claims involve mesothelioma, a rare and aggressive cancer caused primarily by the inhalation or ingestion of asbestos fibers. Johnson &John...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Patients with mesothelioma are being recruited by the National Cancer Institute for a phase II clinical trial using a novel immunotoxin prior to pembrolizumab, a combination that has shown preliminary evidence of efficacy. This promising mesothelioma clinical trial involves the drug LMB-100, designed to make immunotherapy agents such as pembrolizumab, otherwise known as Keytruda, more effective. NCI’s trial includes separate cohorts for pleural and peritoneal types of mesothelioma. “This is a very good option for these patients,” medical oncologist Dr. Raffit Hassan, an acclaimed investigator at the Natio...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Babies | Cancer | Cancer & Oncology | Environmental Health | Epidemiology | Food and Drug Administration (FDA) | Hospitals | Laboratory Medicine | Lawsuits | Legislation | Mesothelioma | Minerals | Occupational Health | Ovarian Cancer | Ovaries | Pathology | Research | Science | Study | Toxicology | USA Health | Women